Tumor Biology

, Volume 35, Issue 2, pp 1287–1295 | Cite as

miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway

  • Weiguo Cao
  • Weiping Yang
  • Rong Fan
  • Hao Li
  • Jinsong Jiang
  • Mei Geng
  • Yening Jin
  • Yunlin Wu
Research Article

Abstract

The purposes of this study were to determine the expression profiles of microRNA-34a (miR-34a) in human gastric cancer cell line (SGC-7901) and cisplatin-resistant cell lines (SGC-7901/DDP), and to establish the correlation between miR-34a expression profile and the sensitivity of human gastric cancer cell to cisplatin-based pattern, thereby providing new methods and strategies for treating gastric cancer. Gastric cancer cell line (SGC-7901) and cisplatin-resistant cell line (SGC-7901/DDP) were cultivated in vitro, respectively. Quantitative real-time PCR (qRT-PCR) and Western blot were utilized to determine the expression profiles of miR-34a and survivin in both gastric cancer cell lines. With miR-34a mimic and miR-34a inhibitor transfected into SGC-7901 and SGC-7901/DDP for 48 h, post-transfection changes of miR-34a expression was determined; the effects of miR-34a ectopic expression on the viability of cisplatin-induce gastric cancer cell were assayed by the MTT method. The effects of miR-34a ectopic expression on apoptosis of cisplatin-induce gastric cancer cell were determined by Annexin V/propidium iodide (PI) double staining method and flow cytometry. The effects of miR-34a ectopic expression on the AKT and p-AKT expression of cisplatin-induce gastric cancer cells were determined by Western blot and flow cytometry with the PI3K pathway inhibitor Wortmannin. As shown by qRT-PCR and Western blot analyses, the expression of miR-34a in cisplatin-resistant cell lines decreased significantly in comparison to that of SGC-7901 cell line (p < 0.05), while significant up-regulation of survivin expression was also observed (p < 0.05). Compared with the control group, the expression of miR-34a increased significantly in SGC-7901 cells transfected with miR-34a mimic for 48 h (p < 0.01). After miR-34a inhibitor transfection, the expression of miR-34a decreased significantly (p < 0.05). The viability of cisplatin-induce gastric cancer cells increased significantly (p < 0.05) with significant decrease of apoptosis after miR-34a expression inhibition, as demonstrated by MTT and flow cytometry with miR-34a over-expression, the viability of cisplatin-induce gastric cancer cells decreased significantly (p < 0.05), with significant apoptosis increase (p < 0.05). As shown by Western blot and flow cytometry, in comparison to the control group, Wortmannin could inhibit miR-34a inhibitor and DDP induced up-regulation of p-AKT significantly (p < 0.05) and stimulated apoptosis. In conclusion, miR-34a expression was down-regulated in cisplatin-resistant cell lines. miR-34a over-expression could improve the sensitivity of gastric cancer cells against cisplatin-based chemotherapies, with PI3K/AKT/survivin signaling pathway possibly involved in the mechanism.

Keywords

Gastric cancer miR-34a Cisplatin Apoptosis PI3K/AKT/survivin 

References

  1. 1.
    Li XJ, Xie HL, Lei SJ, et al. Reduction of CAII expression in gastric cancer: correlation with invasion and metastasis. Chin J Cancer Res. 2012;24:196–200.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Shan F, Ji J. Updating advances and controversies on the multidisciplinary therapy of gastric cancer. Transl Gastrointest Cancer. 2012;1:151–60.Google Scholar
  3. 3.
    Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Wu A, Ji J. The 7th National Gastric Cancer Academic Conference: focus on translational research in gastric cancer. Transl Gastrointest Cancer. 2012;1:277–83.Google Scholar
  5. 5.
    Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions: where do we go? Dig Dis. 2012;30:268–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Sun Y, Tian MM, Zhou LX, et al. Value of c-Met for predicting progression of precancerous gastric lesions in rural Chinese population. Chin J Cancer Res. 2012;24:18–22.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Zhang CD, Zeng YJ, Li HW, et al. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis. Cancer Invest. 2013.Google Scholar
  8. 8.
    Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhao X, Li X, Yuan H. microRNAs in gastric cancer invasion and metastasis. Front Biosci. 2013;18:803–10.CrossRefGoogle Scholar
  10. 10.
    Sanford M. S-1 (teysuno((R))): a review of its use in advanced gastric cancer in non-Asian populations. Drugs. 2013;73(8):845–55.PubMedCrossRefGoogle Scholar
  11. 11.
    Ema A, Yamashita K, Sakuramoto S, et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2013.Google Scholar
  12. 12.
    Chen XL, Chen XZ, Yang C, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8(4):e60320.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Taketa T, Sudo K, Wadhawa R, et al. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15(2):146–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Shi WT, Wei L, Xiang J, et al. Chinese patients with gastric cancer need targeted adjuvant chemotherapy schemes. Asian Pac J Cancer Prev. 2012;13(10):5263–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Huang JY, Xu YY, Sun Z, et al. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4379–85.PubMedCrossRefGoogle Scholar
  16. 16.
    Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–258.PubMedCrossRefGoogle Scholar
  17. 17.
    Wiwanitkit S, Wiwanitkit V. MicroRNA from tuberculosis RNA: a bioinformatics study. J Thorac Dis. 2012;4(3):296–7.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Lee CH, Chiu YC, Wang LB, Kuo YL, Chuang EY, Lai LC, et al. Common applications of next-generation sequencing technologies in genomic research. Transl Cancer Res. 2013;2(1):33–45.Google Scholar
  19. 19.
    Zhou X, Yuan P, He Y. Role of microRNAs in peripheral artery disease (review). Mol Med Report. 2012;6(4):695–700.Google Scholar
  20. 20.
    McDaniel K, Correa R, Zhou T, et al. Functional role of microvesicles in gastrointestinal malignancies. Ann Transl Med. 2013;1:4.PubMedCentralPubMedGoogle Scholar
  21. 21.
    Ui-Tei K, Nishi K, Takahashi T, et al. Thermodynamic control of small RNA-mediated gene silencing. Front Genet. 2012;3:101.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Yang JS, Maurin T, Lai EC. Functional parameters of Dicer-independent microRNA biogenesis. RNA. 2012;18(5):945–57.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9(6):850–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther. 2012;12(9):1221–39.PubMedCrossRefGoogle Scholar
  25. 25.
    Yamamoto H, Adachi Y, Taniguchi H, et al. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol. 2012;18(22):2745–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Wong MY, Yu Y, Walsh WR, et al. microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol. 2011;38(5):1189–95.PubMedGoogle Scholar
  27. 27.
    O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12(2):201.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Cha YH, Kim NH, Park C, et al. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11(7):1273–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Balca-Silva J, Neves SS, Goncalves AC, et al. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res. 2012;32(5):1603–9.PubMedGoogle Scholar
  30. 30.
    Cao W, Fan R, Wang L, et al. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol. 2013;34(2):963–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. J Cell Physiol. 2013.Google Scholar
  32. 32.
    Li XJ, Ji MH, Zhong SL, et al. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res. 2012;43(7):514–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Yao Y, Suo AL, Li ZF, et al. MicroRNA profiling of human gastric cancer. Mol Med Report. 2009;2(6):963–70.Google Scholar
  34. 34.
    Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011;3(1):83–92.PubMedCrossRefGoogle Scholar
  35. 35.
    Kumar B, Yadav A, Lang J, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012;7(5):e37601.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Shen Z, Zhan G, Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol. 2012;29(4):2473–80.PubMedCrossRefGoogle Scholar
  37. 37.
    Jagadeesh D, Smith MR. Novel targeted therapies in peripheral T cell lymphoma. Discov Med. 2013;15(85):367–78.PubMedGoogle Scholar
  38. 38.
    Morotti M, Becker C, Menada MV, et al. Targeting tyrosine-kinase in ovarian cancer. Expert Opin Investig Drugs. 2013.Google Scholar
  39. 39.
    Lubin J, Markowska A, Knapp P. Factors affecting response of chemotherapy in women with ovarian cancer. Eur J Gynaecol Oncol. 2012;33(6):644–7.PubMedGoogle Scholar
  40. 40.
    Breier A, Gibalova L, Seres M, et al. New insight into P-glycoprotein as a drug target. Anticancer Agents Med Chem. 2013;13(1):159–70.PubMedCrossRefGoogle Scholar
  41. 41.
    De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17–27.PubMedCrossRefGoogle Scholar
  42. 42.
    Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40(1):139–46.PubMedCrossRefGoogle Scholar
  43. 43.
    Du F, Wu X, Liu Y, et al. Acquisition of paclitaxel resistance via PI3K-dependent epithelial–mesenchymal transition in A2780 human ovarian cancer cells. Oncol Rep. 2013.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Weiguo Cao
    • 1
  • Weiping Yang
    • 2
  • Rong Fan
    • 3
  • Hao Li
    • 1
  • Jinsong Jiang
    • 1
  • Mei Geng
    • 1
  • Yening Jin
    • 1
  • Yunlin Wu
    • 3
  1. 1.Department of Oncology, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  2. 2.Department of General Surgery, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina
  3. 3.Department of Gastroenterology, Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina

Personalised recommendations